Clinical Trials Browser

Interventional × vatalanib × Clear all

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT00358163 2022-04-29

Trial of PTK787/ZK 222584 Plus Paclitaxel

Phase 1 Terminated

Metastatic Non-hematologic Malignancies

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

Phase 1/2 Terminated

Melanoma

NCT00056459 2020-02-10

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Phase 3 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00390000 2019-04-08

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00348790 2018-10-26

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Phase 2 Completed

25 enrolled 10 charts

Hemangiopericytoma, Malignant, Brain Neoplasms, Meningioma, Sarcoma, Central Nervous System Neoplasms

NCT00268918 2018-07-27

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Phase 2 Completed

von Hippel-Lindau Disease, Hemangioblastoma

NCT00072475 2016-08-01

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Phase 2 Completed

155 enrolled 10 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT00053885 2016-07-01

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00303732 2016-03-03

PTK/RAD

Phase 1 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00216047 2015-12-09

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00134355 2015-01-19

Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00160043 2014-12-16

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00511043 2014-12-09

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT00240162 2014-09-17

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Phase 2 Terminated

21 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00185588 2014-09-15

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Phase 1/2 Completed

33 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00731861 2014-09-11

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Phase 1 Completed

Carcinoma, Neoplasm Metastasis

NCT00385853 2013-10-21

PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs

Phase 1 Completed

Glioblastoma

NCT00563823 2013-08-02

Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery

Phase 2 Completed

Melanoma

NCT00263198 2013-05-07

PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00293371 2012-10-11

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Phase 1/2 Terminated

Prostatic Neoplasms

NCT00128700 2012-09-24

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1/2 Completed

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00226005 2012-05-09

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Phase 2 Completed

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT00281125 2012-03-19

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

Phase 1/2 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT00088231 2012-01-20

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Phase 1/2 Completed

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT00590343 2011-06-29

PTK787

Phase 2 Completed

Neuroendocrine Tumors

NCT00117299 2010-05-27

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

Phase 2 Completed

GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

NCT00171587 2009-11-19

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

Phase 1/2 Completed

Neoplasm Metastasis, Neoplasms

NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Phase 1 Completed

Neoplasms

NCT00165347 2007-12-21

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell